MedTrace Logo

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT05338931 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2022-05-26

No results posted yet for this study

Summary

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

DRUG

AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

Anti-CD19 Chimeric Antigen Receptor T cell

Sponsors & Collaborators

  • AbClon

    lead INDUSTRY

Principal Investigators

  • Deok-hyun Yoon · Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2030-03-15
Completion
2030-09-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05338931 on ClinicalTrials.gov